BMRN — Biomarin Pharmaceutical Cashflow Statement
0.000.00%
Last trade - 00:00- $10.41bn
- $9.45bn
- $3.22bn
Annual cashflow statement for Biomarin Pharmaceutical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -64.1 | 142 | 168 | 427 | 349 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 210 | 80.8 | 269 | 210 | 644 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 66 | -96.4 | -337 | -216 | -294 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 305 | 176 | 159 | 573 | 828 |
| Capital Expenditures | -119 | -132 | -108 | -97.4 | -111 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | -247 | 112 | -3.63 | 234 | -303 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -366 | -20 | -111 | 136 | -414 |
| Financing Cash Flow Items | -46.2 | -85.4 | -85.8 | -77.6 | -56.9 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | -0.048 | -18.6 | -18.7 | -526 | -42.4 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -61.9 | 137 | 30.6 | 188 | 369 |